Research Use Only — Not for Human or Veterinary Use.
Sign in
‹ Library

Cagrilintide + GLP-1 Blend

Blend & StackResearch Use Only

Also known as: CagriSema-style Blend, Cagri + GLP-1

This blend combines Cagrilintide (a long-acting amylin analog) with a GLP-1 receptor agonist (such as semaglutide in the CagriSema-style combination). The two are grouped in research literature because they are studied for complementary metabolic and appetite-signaling pathways, with amylin and GLP-1 mechanisms investigated together.

Typical range (research)
Commonly referenced research ranges per component vary widely by protocol; both amylin analogs and GLP-1 agonists are typically referenced at low milligram or sub-milligram weekly amounts. The 10 mg total supports repeated study doses.
Half-life
Varies by component
Route
Subcutaneous (research)
Common use
Metabolic and appetite-signaling research
Common vial sizes
10 mg total
Storage
Refrigerate reconstituted solution at 2-8 C; keep powder cold until reconstitution.
Stacking notes
Components: Cagrilintide (amylin analog), a GLP-1 receptor agonist (e.g. semaglutide).

Reported side effects

Nausea reported anecdotallyReduced appetiteGastrointestinal discomfort reported anecdotallyHuman data limited in this specific blend form
Regulatory note: GLP-1 receptor agonists such as semaglutide are approved prescription drugs in Canada and other jurisdictions; this blend contains a regulated pharmaceutical component.
Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.